City Therapeutics was reported to have raised $99.5 million for its RNA interference drug development platform. The round provides substantial private capital for programs that must move through expensive scientific and clinical validation.
Biotechnology financing is returning selectively to platforms with a clear path to evidence. Unlike software, product iteration is bounded by biology and trial design, which makes portfolio…
Continue reading with a digital subscription
Unlock original reporting on business, startups, venture capital, private equity, M&A, IPOs and AI. Payments will be activated after the business account is connected.
Reporting basis
Public Equity reviewed the following reporting material before independently writing this story.
